The stock offers roughly 34% upside to analyst consensus with a 6-to-1 reward-to-risk ratio, but a confirmed technical downtrend is a hard block for near-term entry, and the thesis rests on two concentrated products whose clinical pipeline adds binary risk.
Thesis pillars
- Strong Quality Metrics→Stable
- Wide Dislocation Favorable Asymmetry→Stable
- Technical Downtrend Hard Block→Stable
- +1 more pillar — see the Why tab for full reasoning
ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. At $25.86, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: NUPLAZID and DAYBUE; Concentration risk — Pipeline: remlifanserin RADIANT Phase 2.
ACADIA Pharmaceuticals commercializes two neurological drugs with FDA exclusivity: NUPLAZID (pimavanserin), the only FDA-approved treatment for Parkinson's disease psychosis since April 2016, and DAYBUE (trofinetide), the only FDA-approved treatment for Rett syndrome since March... Read more
Sell if holding. At $25.86, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: NUPLAZID and DAYBUE; Concentration risk — Pipeline: remlifanserin RADIANT Phase 2. Chart setup: Death cross but MACD improving, RSI 87. Score 5.2/10, high confidence.
Passes 7/11 gates (positive momentum, clean insider activity, news boost analyst 0.40, news boost analyst cluster(3), earnings proximity 33d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.
About ACADIA Pharmaceuticals Inc.
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals generated $1,071.5 million in net product sales in 2025 — up from $957.8 million in 2024 — split between NUPLAZID (pimavanserin), the only FDA-approved treatment for Parkinson's disease psychosis since April 2016, and DAYBUE (trofinetide), the only FDA-approved treatment for Rett syndrome since March 2023. DAYBUE received Health Canada marketing authorization in October 2024 and Israeli Ministry of Health approval in December 2025, beginning international expansion from a predominantly U.S. commercial base. In December 2025, the FDA approved DAYBUE STIX, a powder reformulation offering additional dosing flexibility.
Revenue flows from prescription drug sales through a limited network of specialty distributors and specialty pharmacies in the U.S. NUPLAZID targets an estimated 130,000 Parkinson's disease patients treated annually with atypical antipsychotics in the United States, with roughly 20% currently using NUPLAZID; the company has a stated goal of $1.0 billion in NUPLAZID net sales in 2028. DAYBUE addresses an estimated 6,000 to 9,000 Rett syndrome patients in the U.S., with growth depending on new patient adoption and persistency rates. Competitors for NUPLAZID include off-label use of generics such as quetiapine, clozapine, risperidone, aripiprazole, and olanzapine. DAYBUE faces competitive programs including UCB S.A.'s announced plans to initiate a Phase 3 trial of fenfluramine in Rett syndrome during 2026, as well as gene therapy trials by Taysha Gene Therapies and Neurogene. The Medicare Drug Price Negotiation Program could subject NUPLAZID to HHS-negotiated pricing as early as 2029, when the company believes it may qualify as a specified small manufacturer eligible for a phase-in discount.
Show full overview
The lead pipeline candidate, remlifanserin (ACP-204), is in a Phase 2 RADIANT study for Alzheimer's disease psychosis; enrollment is expected to complete in the first half of 2026, with top-line results anticipated in the August to October 2026 timeframe. A positive readout would advance remlifanserin into two Phase 3 studies with nearly identical design. A negative result would follow three consecutive trial failures — Phase 3 ADVANCE-2 for pimavanserin in schizophrenia (March 2024), a pediatric autism Phase 2 (October 2024), and Phase 3 COMPASS PWS for intranasal carbetocin (September 2025) — leaving the pipeline to Phase 2 assets in Lewy Body Dementia psychosis and early-stage programs in major depressive disorder and essential tremor. In April 2026, ACADIA disclosed via Form 8-K the planned retirement of Dr. Elizabeth Thompson, Head of Research and Development, with a search for a replacement underway during this critical readout period.
See also: Healthcare · Biotechnology
From ACADIA Pharmaceuticals Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-06Recent Developments — ACADIA Pharmaceuticals Inc.
Latest news
- NEWS Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance — Yahoo Finance positive
- NEWS ACADIA Pharmaceuticals (ACAD) to Release Earnings on Wednesday - MarketBeat — MarketBeat neutral
- NEWS ACADIA PHARMACEUTICALS ($ACAD) Releases Q1 2026 Earnings - Quiver Quantitative — Quiver Quantitative neutral
- NEWS R&D Leadership Transition and Trial Continuity Could Be A Game Changer For ACADIA Pharmaceuticals (ACAD) - Sahm — Sahm positive
- NEWS ACADIA Pharmaceuticals (ACAD) Stock Could Be 23.2% Undervalued After Guidance Reaffirmed - simplywall.st — simplywall.st positive
Generated 2026-07-06T05:40:26Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductNUPLAZID and DAYBUE10-K Item 1: 'We have two products that are approved for commercialization in the U.S.: NUPLAZID and DAYBUE'
- HIGHpipelineremlifanserin RADIANT Phase 210-K Item 1: 'Phase 2 RADIANT study of remlifanserin ... report top-line results in the August to October 2026 timeframe'
Material Events(8-K, last 90d)
- 2026-05-01Item 5.02MEDIUMElizabeth H.Z. Thompson, Ph.D., Head of Research and Development, announced planned retirement on April 27, 2026. Will continue in role until successor appointed, then consult through end of 2026. Company initiated search for replacement.SEC filing →
- 2026-05-29Item 5.02LOWStockholders approved amendment to 2024 Equity Incentive Plan at May 29, 2026 Annual Meeting, increasing shares authorized for issuance by 5,209,670. Routine equity plan amendment; no officer departure.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $25.86, A.R:R 0.8:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: NUPLAZID and DAYBUE; Concentration risk — Pipeline: remlifanserin RADIANT Phase 2. Chart setup: Death cross but MACD improving, RSI 87. Prior stop was $24.15. Score 5.2/10, high confidence.
Take-profit target: $29.07 (+11.9% upside). Prior stop was $24.15. Stop-loss: $24.15.
Concentration risk — Product: NUPLAZID and DAYBUE; Concentration risk — Pipeline: remlifanserin RADIANT Phase 2; Earnings expected to decline ~60% (cyclical peak).
ACADIA Pharmaceuticals Inc. trades at a P/E of 11.8 (forward 29.4). TrendMatrix value score: 5.2/10. Verdict: Sell.
27 analysts cover ACAD with a consensus score of 4.0/5. Average price target: $32.
What does ACADIA Pharmaceuticals Inc. do?ACADIA Pharmaceuticals commercializes two neurological drugs with FDA exclusivity: NUPLAZID (pimavanserin), the only...
ACADIA Pharmaceuticals commercializes two neurological drugs with FDA exclusivity: NUPLAZID (pimavanserin), the only FDA-approved treatment for Parkinson's disease psychosis since April 2016, and DAYBUE (trofinetide), the only FDA-approved treatment for Rett syndrome since March 2023. Combined net product sales were $1,071.5 million in 2025, distributed through a limited network of specialty pharmacies and distributors in the United States.